生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

已收盘 12-11 16:00:00 EST

1,117.74

+5.87

+0.53%

最高1,121.91	最低1,110.20	成交量7.02亿
今开1,111.87	昨收1,111.87	日振幅1.05%
总市值0.00	流通市值0.00	总股本0.00
成交额152.35亿	换手率--	流通股本0.00
市净率7.03811	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1117.7389,"timestamp":1765486799999,"preClose":1111.8706,"halted":0,"volume":702258207,"delay":0,"changeRate":0.005278,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":5.868286,"latestTime":"12-11 16:00:00 EST","open":1111.8682,"high":1121.9083,"low":1110.1953,"amount":15234501627.790552,"amplitude":0.010535,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.03811,"peRate":-124.516039,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1172114110","title":"AlphaTON Capital Corp.与Atnorth达成首个重大数据中心协议，确保瑞典2.2兆瓦高性能计算能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1172114110","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172114110?lang=zh_cn&edition=full","pubTime":"2025-12-12 03:45","pubTimestamp":1765482309,"startTime":"0","endTime":"0","summary":"AlphaTON Capital Corp.与Atnorth达成首个重大数据中心协议，确保瑞典2.2兆瓦高性能计算能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATON"],"gpt_icon":0},{"id":"1151282268","title":"Celcuity在2025年圣安东尼奥乳腺癌研讨会上展示Pik3CA野生型队列的Viktoria-1三期试验更新结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1151282268","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151282268?lang=zh_cn&edition=full","pubTime":"2025-12-12 03:35","pubTimestamp":1765481711,"startTime":"0","endTime":"0","summary":"Celcuity在2025年圣安东尼奥乳腺癌研讨会上展示Pik3CA野生型队列的Viktoria-1三期试验更新结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"gpt_icon":0},{"id":"1148610518","title":"凯信远达 - 投资用于资助中国阶段1肾移植抗体介导排斥反应研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1148610518","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148610518?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:12","pubTimestamp":1765462338,"startTime":"0","endTime":"0","summary":"凯信远达 - 投资用于资助中国阶段1肾移植抗体介导排斥反应研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CASI"],"gpt_icon":0},{"id":"1166602535","title":"Rezolute高管表示，因严重过敏反应而停药的两名患者未检测到阳性抗药物抗体 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1166602535","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166602535?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:11","pubTimestamp":1765462283,"startTime":"0","endTime":"0","summary":"Rezolute高管表示，因严重过敏反应而停药的两名患者未检测到阳性抗药物抗体 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RZLT","BK4139"],"gpt_icon":0},{"id":"1151710553","title":"MAIA Biotechnology宣布在Thio-104三期关键试验中首次为患者使用Ateganosine，作为晚期非小细胞肺癌的三线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1151710553","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151710553?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:02","pubTimestamp":1765461732,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology宣布在Thio-104三期关键试验中首次为患者使用Ateganosine，作为晚期非小细胞肺癌的三线治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"1136341643","title":"Rezolute高管表示，63名参与者中有四名因不良事件早期终止研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1136341643","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136341643?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:54","pubTimestamp":1765461255,"startTime":"0","endTime":"0","summary":"Rezolute高管表示，63名参与者中有四名患者因不良事件早期终止了研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RZLT","BK4139"],"gpt_icon":0},{"id":"1164504881","title":"杰龙股价盘前上涨2.3%；公司宣布战略重组计划，全员裁减三分之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1164504881","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164504881?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:10","pubTimestamp":1765458621,"startTime":"0","endTime":"0","summary":"杰龙股价盘前上涨2.3%；公司宣布战略重组计划，全员裁减三分之一","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GERN"],"gpt_icon":0},{"id":"1189846262","title":"Absci公布新的人体外数据，显示Abs-201™能刺激毛发生长并再生干细胞微环境，可能逆转毛囊微型化","url":"https://stock-news.laohu8.com/highlight/detail?id=1189846262","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189846262?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:09","pubTimestamp":1765458596,"startTime":"0","endTime":"0","summary":"Absci公布新的人体外数据，显示Abs-201™能刺激毛发生长并再生干细胞微环境，可能逆转毛囊微型化","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABSI","BK4139","BK4539"],"gpt_icon":0},{"id":"1104472090","title":"Savara宣布欧洲专利局计划授予Molbreevi液体制剂专利","url":"https://stock-news.laohu8.com/highlight/detail?id=1104472090","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104472090?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:06","pubTimestamp":1765458399,"startTime":"0","endTime":"0","summary":"Savara宣布欧洲专利局计划授予Molbreevi液体制剂专利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"1126433588","title":"Elicio Therapeutics报告在进行中的第2阶段Amplify-7P试验中，抗原传播扩展至患者特异性新抗原超越Mkras","url":"https://stock-news.laohu8.com/highlight/detail?id=1126433588","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126433588?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:05","pubTimestamp":1765458343,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics报告在进行中的第2阶段Amplify-7P试验中，抗原传播扩展至患者特异性新抗原超越Mkras","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"1187699067","title":"杰龙公司公布战略重组计划以为长期价值创造奠定基础","url":"https://stock-news.laohu8.com/highlight/detail?id=1187699067","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187699067?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:01","pubTimestamp":1765458104,"startTime":"0","endTime":"0","summary":"杰龙公司公布战略重组计划以为长期价值创造奠定基础","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"1105658123","title":"Praxis Precision Medicines宣布将在2026年初提交Relutrigine针对SCN2A和SCN8A发育性及癫痫脑病的NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1105658123","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105658123?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:01","pubTimestamp":1765458098,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines宣布将在2026年初提交Relutrigine针对SCN2A和SCN8A发育性及癫痫脑病的NDA申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","PRAX","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"1157010904","title":"Centessa Pharmaceuticals PLC 任命Mario Alberto Accardi为首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1157010904","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157010904?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:57","pubTimestamp":1765457848,"startTime":"0","endTime":"0","summary":"12月11日 - Centessa Pharmaceuticals PLC（）宣布任命Mario Alberto Accardi为首席执行官，并将于2026年1月1日生效，Saurabh Saha将卸任首席执行官。此外，Centessa Pharmaceuticals PLC还透露，ORX750的注册项目预计将在2026年第一季度启动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4535","CNTA"],"gpt_icon":0},{"id":"1181940294","title":"Rezolute股价在盘前暴跌91.3%，原因是罕见疾病药物在晚期研究中未能达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1181940294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181940294?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:47","pubTimestamp":1765457249,"startTime":"0","endTime":"0","summary":"Rezolute股价在盘前暴跌91.3%，原因是罕见疾病药物在晚期研究中未能达到主要目标","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RZLT","BK4139"],"gpt_icon":0},{"id":"1156157191","title":"AC Immune股价在盘前交易中上涨32.6%，因公司公布帕金森病疗法的积极试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1156157191","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156157191?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:40","pubTimestamp":1765456816,"startTime":"0","endTime":"0","summary":"AC Immune股价在盘前交易中上涨32.6%，因公司公布帕金森病疗法的积极试验数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACIU","BK4139"],"gpt_icon":0},{"id":"1104547270","title":"Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日","url":"https://stock-news.laohu8.com/highlight/detail?id=1104547270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104547270?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:39","pubTimestamp":1765456740,"startTime":"0","endTime":"0","summary":"Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"1184614665","title":"Rhythm Pharmaceuticals公布探索性第二阶段试验的初步数据，显示Setmelanotide在Prader-Willi综合症中展现了积极的疗效信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1184614665","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184614665?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:32","pubTimestamp":1765456337,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals公布探索性第二阶段试验的初步数据，显示Setmelanotide在Prader-Willi综合症中展现了积极的疗效信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"1103258053","title":"Rhythm Pharmaceuticals Inc.：安全性和耐受性结果与Setmelanotide公认的临床特征一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1103258053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103258053?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:32","pubTimestamp":1765456335,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.：安全性和耐受性结果与Setmelanotide公认的临床特征一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"1147625527","title":"AC Immune关于ACI-7104.056的积极中期II期数据支持潜在减缓帕金森病进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1147625527","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147625527?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:08","pubTimestamp":1765454928,"startTime":"0","endTime":"0","summary":"AC Immune关于ACI-7104.056的积极中期II期数据支持潜在减缓帕金森病进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACIU"],"gpt_icon":0},{"id":"1176633270","title":"万春药业公布Dublin-3 III期研究的新分析结果，显示Plinabulin + Docetaxel在抗Pd-(L)1治疗后对于非鳞状EGFR野生型NSCLC的生存获益，以及与Docetaxel相比脑转移减少情况，在NACLC 2025上发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1176633270","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176633270?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:07","pubTimestamp":1765454841,"startTime":"0","endTime":"0","summary":"万春药业公布Dublin-3 III期研究的新分析结果，显示Plinabulin + Docetaxel在抗Pd-(L)1治疗后对于非鳞状EGFR野生型NSCLC的生存获益，以及与Docetaxel相比脑转移减少情况，在NACLC 2025上发布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}